<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33964</article-id><article-id pub-id-type="doi">10.26442/20795696.2020.1.200015</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The occurrence of human papillomavirus types in the formation of neoplastic transformation of the epithelium of the cervix in “lesser abnormalies”</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязь типов вируса папилломы человека с прогрессированием процесса и формированием неопластической трансформации эпителия у пациенток с «малыми» формами поражения шейки матки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sycheva</surname><given-names>Elena G.</given-names></name><name xml:lang="ru"><surname>Сычева</surname><given-names>Елена Геннадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>doctor</p></bio><bio xml:lang="ru"><p>врач научно-поликлинического отд-ния</p></bio><email>el.bona@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9499-7654</contrib-id><name-alternatives><name xml:lang="en"><surname>Nazarova</surname><given-names>Niso M.</given-names></name><name xml:lang="ru"><surname>Назарова</surname><given-names>Нисо Мирзоевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед наук, вед. науч. сотр. научно-поликлинического отд-ния</p></bio><email>grab2@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Burmenskaya</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Бурменская</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Biol.)</p></bio><bio xml:lang="ru"><p>д-р биол. наук, ст. науч. сотр. лаб. молекулярно-генетических методов</p></bio><email>bourmenska@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7643-8346</contrib-id><name-alternatives><name xml:lang="en"><surname>Prilepskaya</surname><given-names>Vera N.</given-names></name><name xml:lang="ru"><surname>Прилепская</surname><given-names>Вера Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зам. дир. по научной работе, зав. научно-поликлиническим отд-нием</p></bio><email>VPrilepskaya@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1569-8486</contrib-id><name-alternatives><name xml:lang="en"><surname>Trofimov</surname><given-names>Dmitry Yu.</given-names></name><name xml:lang="ru"><surname>Трофимов</surname><given-names>Дмитрий Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Biol.), Prof. RAS</p></bio><bio xml:lang="ru"><p>проф. РАН, д-р биол. наук, дир. Института репродуктивной генетики</p></bio><email>d.trofimov@dna-tech.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-01" publication-format="electronic"><day>01</day><month>05</month><year>2020</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>19</fpage><lpage>22</lpage><history><date date-type="received" iso-8601-date="2020-05-01"><day>01</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-05-01"><day>01</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/33964">https://gynecology.orscience.ru/2079-5831/article/view/33964</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To assess the frequency of human papillomavirus (HPV) occurrence according to the IARC classification in patients with “lesser abnormalie” of cervical epithelial lesions and analyze their role in the formation of SIL.</p> <p><bold>Materials and methods. </bold>The study included 129 HPV-positive women aged 18–45 years (average age 34 to 11 years) with cytological conclusion NILM, ASCUS or LSIL. Patients are divided into 3 groups depending on the results of the cytological smear: 1 group (NILM/HPV) – 66 (51.2%), 2 group (ASCUS/HPV) – 28 (21.7%), 3 group (LSIL/HPV) – 35 (27.1%). During dynamic observation for 24 months. A comprehensive clinical-laboratory examination was carried out, including HPV-typing, cytological examination, extended colposcopy every 6 months, sighting biopsy of the cervix (according to the indications).</p> <p><bold>Results. </bold>According to the results of the pathomorphological study, squamous intraepithelial lesions neoplasia (cervical intraepithelial neoplasia – CIN+) was verified in 59 (71.9%) of the results of the study: LSIL (CIN I) – 53 (64.6%), HSIL (CIN II–III) – 6 (4.6%). The morphological diagnosis of LSIL (CIN I) was established in 1 group (NILM/HPV+) in 20 (55.6%), 2 groups (ASCUS/HPV+) – 9 (32%), 3 group (LSIL/HPV) – 24 (68.6%); HSIL (CIN II–III) in group 1 – 2 (5.6%), in 2 group – 3 (10.7%) and in the 3 group – 1 (2.9%).</p> <p><bold>Conclusions. </bold>In patients with “lesser abnormalies” of cervical lesions in the formation of CIN+ participated HPV group 1 – in 79.1%, groups 2A – in 5.5%, groups 2B – in 15.4% of cases. The HPV high carcinogenic risk (group 1) was involved in the formation of HSIL (CIN II–III). The neoplastic transformation of the cervical epithelium of the studied patients was caused by the persistence of HPV 16, 58, 39, 18, 51, 68, 56, 82, 35, 52, 53, 35 types.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Изучить наиболее часто встречаемые типы вируса папилломы человека (ВПЧ), участвующие в формировании неопластической трансформации эпителия шейки матки, у пациенток с «малыми» формами поражения.</p> <p><bold>Материалы и методы. </bold>В исследование включены 129 ВПЧ-положительных женщин в возрасте 18–45 лет (средний возраст 34±11 лет) с цитологическим заключением NILM, ASCUS и LSIL. Пациентки разделены на 3 группы в зависимости от результатов цитологического мазка: 1-я группа (NILM/ВПЧ+) – 66 (51,2%), 2-я группа (ASCUS/ВПЧ+) – 28 (21,7%), 3-я группа (LSIL/ВПЧ+) – 35 (27,1%). В ходе динамического наблюдения в течение 24 мес проведено комплексное клинико-лабораторное обследование, включающее ВПЧ-типирование, цитологическое исследование, расширенную кольпоскопию, прицельную биопсию шейки матки (по показаниям).</p> <p><bold>Результаты. </bold>По результатам патоморфологического исследования верифицированы плоскоклеточные интраэпителиальные неоплазии (цервикальная интраэпителиальная неоплазия – CIN+) в 59 (71,9%) случаях, из них LSIL (CIN I) – 53 (64,6%), HSIL (CIN II–III) – 6 (4,6%) случаев. Морфологический диагноз LSIL (CIN I) установлен в 1-й группе (NILM/ВПЧ+) у 20 (55,6%), во 2-й группе (ASCUS/ВПЧ+) – 9 (32%), в 3-й группе (LSIL/ВПЧ+) – 24 (68,6%); HSIL (CIN II–III) в 1-й группе – 2 (5,6%), во 2-й группе – 3 (10,7%) и в 3-й группе – 1 (2,9%).</p> <p><bold>Заключение. </bold>У пациенток с «малыми» формами поражения шейки матки в формировании CIN+ участвовали типы ВПЧ группы 1 – в 79,1%, группы 2А – в 5,5%, группы 2В – в 15,4% случаев. В формировании HSIL (CIN II–III) участвовали типы ВПЧ высокого канцерогенного риска (группа 1). Неопластическая трансформация эпителия шейки матки исследуемых пациенток была обусловлена персистенцией ВПЧ 16, 58, 39, 18, 51, 68, 56, 82, 35, 52, 53, 35-го типов.</p> <p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>“lesser abnormalies” lesions</kwd><kwd>cervical intraepithelial neoplasia</kwd><kwd>human papillomavirus</kwd><kwd>cervical cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>«малые» формы поражения шейки матки</kwd><kwd>цервикальная интраэпителиальная неоплазия</kwd><kwd>вирус папилломы человека</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Massad LS, Einstein MH, Huh WK et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer prcursors. Obstet Gynecol 2013; 121 (4): 829–46.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fujiwara H, Suzuki M, Morisawa H et al. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan. Asian Pac J Cancer Prev 2019; 20 (1): 81–5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kang WD, Ju UC, Kim SM. Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology? Gynecol Oncol 2018; 148 (2): 305–10.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Сычева Е.Г., Назарова Н.М., Бурменская О.В. и др. Персистенция ВПЧ высокого онкогенного риска и другие молекулярно-генетические предикторы развития цервикальных интраэпителиальных неоплазий. Акушерство и гинекология. 2018; 12: 104–10. [Sycheva E.G., Nazarova N.M., Burmenskaya O.V. et al. High-risk human papillomavirus persistence and other molecular genetic predictors for cervical intraepithelial neoplasias. Obstetrics and Gynecology. 2018; 12: 104–10 (in Russian).]</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>De Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445 (1–2): 2–10.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Burd EM. Human Papillomavirus Laboratory Testing: the Changing Paradigm. Clin Microbiol Rev 2016; 29 (2): 291–319.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. CA Cancer J Clin 2012; 62: 147–72.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Guan P, Howell-Jones R, Li N et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131 (10): 2349–59.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Halec G, Alemany L, Lloveras B et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 234 (4): 441–51.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol 2014; 234 (4): 431–5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wang J, Tang D, Wang J et al. Genotype distribution and prevalence of human papillomavirus among women with cervical cytological abnormalities in Xinjiang, China. Hum Vaccin Immunother 2019; 15 (7–8): 1889–96.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Harari A, Chen Z, Robert D Burk. Human papillomavirus genomics: past, present and future. Curr Probl Dermatol 2014; 45: 1–18.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Yang Z, Cuzick J, Hunt WC, Wheeler CM. Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol 2014; 180 (11): 1066–75.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Schiffman M, Vaughan LM, Raine-Bennett TR et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol 2015; 138: 573–8.</mixed-citation></ref></ref-list></back></article>
